Improving adherence to antiretroviral therapy

AIDS Reader

Volumn 13, Issue 2, 2003, Pages 81-90

  Daar, Eric S ^a,b   Cohen, Calvin ^c   Remien, Robert ^d   Sherer, Renslow ^e,f   Smith, Kimberly ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e RUSH MEDICAL COLLEGE   (United States)

^f The CORE Center   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adherence; Antiretroviral therapy; HIV AIDS; Once daily regimen

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMIVIRINE; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

DIARRHEA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; NAUSEA; PATIENT COMPLIANCE; REVIEW; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; VIRAL LOAD;

EID: 0037308209     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Raboud JM, Harris M, Rae S, Montaner JS. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med. 2002;3:118-124.
2. Mannheimer S, Friedland G, Matts J, et al. Antiretroviral adherence correlates with quality of life. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 485.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
4. Richman DD, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract LB-17.
5. Gebo KA, Keruly JC, Moore RD. Is illicit drug use a risk factor for non-adherence to antiretroviral therapy? In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 477.
6. Kasper TB, Arboleda CH, Halpern M. The impact of patient perceptions of body shape changes and metabolic abnormalities on antiretroviral therapy In: Program and abstracts of the XIIIth International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WePpB1380.
7. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001;28:124-131.
8. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:117-125.
9. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150: 1881-1884.
10. Eron JJ, Berstein B, King M, et al. Once-daily vs twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 48-week follow-up. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 409-W.
11. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.
12. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients: ICONA Study Group. Italian Cohort of Antiretroviral Naive Patients. AIDS. 2000;14:499-507.
13. Staszewski S, Gallant J, Pozniak A, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination-with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. In: Program and abstracts of the XlVth International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract LbOr17.
14. Benson C, Brun S, King M, et al. Two year follow up of ABT-378/ritonavir (ABT-378/r) in antiretroviral naive HIV+ patients. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto. Abstract 546.
15. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001;285:1155-1163.
16. Vibhagool A, Cahn P, Schecter M, et al. Abacavir/Combivir (ABC/COM) is comparable to indinavir/Combivir in HIV-1 infected antiretroviral therapy naive adults: preliminary results of a 48-week open label study (CNA3014). In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires. Abstract 063.
17. Katlama C, Fenske S, Gazzard B, et al. Switch to Trizivir versus continued HAART provides equivalent HIV-1 RNA suppression at 48 weeks (TRIZAL-AZL30002). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 22-25, 2001; Chicago. Abstract I671.
18. Maggiolo F, Migliorino M, Caprioli S, et al. Once-a-day therapy for HIV infection. In: Program and abstracts of the XIIIth International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract TuPpB1167.
19. Molina JM, Perusat S, Ferchal F, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in treatment-naive HIV-infected adults: 64-week follow-up of the ANRS 091 trial. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 321.
20. Feinberg J, Eron J, Berstein B, et al. Once-daily vs twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 48-week follow-up. In: Program and abstracts of the XIVth International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract TuPeB4445.
21. Squires K. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing anti-retroviral strategies versus a standard PI-containing regimen, final 48 week data. In: Program and abstracts of the XlIIth International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract LbPeB7046.
22. Gifford AL, Bormann JE, Shively MJ, et al. Effects of group HIV patient education on adherence to antiretrovirals: a randomized controlled trial. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 479.
23. Andrade A, Davis H, Celano S, et al. Intervention trial using a novel electronic device in HAART initiators: impact of cognitive dysfunction. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 602.
24. Safren S, Boswell S, Johnson W, et al. Initial outcome of an on-line paging system (MediMom) to increase adherence to antiretroviral medications. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 480.